Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis
- Sponsor
- Wei Zhou
- Study ID
- NCT06700421
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
- Unresectable Locally Advanced Non-small Cell Lung Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Adebrelimab + Apatinib — DRUGAdebrelimab combined with apatinib
Study Details
A prospective, single-center, phase II clinical study of adebrelimab combined with apatinib in the treatment of unresectable stage III NSCLC patients with grade ≤2 radiation pneumonitis after definitive chemoradiotherapy
Key Dates
- Start date
- Aug 13, 2024
- Status verified
- Nov 2024
- Primary completion
- Dec 31, 2024
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 32 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Other: Group APatients with grade 0-1 radiation pneumonitis were enrolled and treated with adebrelimab combined with apatinib within 42 days after definitive chemoradiotherapy
- Other: Group BPatients with grade 2 radiation pneumonitis were enrolled and treated with adebrelimab combined with apatinib within 56 days after definitive chemoradiotherapy
Primary Outcome Measure
Progression free survival (PFS) [ Time Frame: Doses were administered every 6 weeks from the first dose of study drug until approximately 12 months ]